Irene Hallyburton

Irene Hallyburton

Auto-generated profile, based on publicly available information

Irene Hallyburton

Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2015 in Nature
Verified
Journal Article
Open access
PDF file
BBBeatriz Baragaña
Beatriz Baragaña
IHIrene Hallyburton
Irene Hallyburton
MLMarcus C. S. Lee
Marcus C. S. Lee
NNNeil R. Norcross
Neil R. Norcross
RGRaffaella Grimaldi
Raffaella Grimaldi
IGIan H. Gilbert
Ian H. Gilbert
There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a potent and novel spectrum of antimalarial activity against multiple life-cycle stages of the Plasmodium parasite, with good pharmacokinetic properties and an acceptable safety profile. DDD107498 demonstrates potential to address a variety of clinical needs, including single-dose treatment, transmission blocking and chemoprotection. DDD107498 was developed from a screening programme against blood-stage malaria parasites; its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis. This discovery of eEF2 as a viable antimalarial drug target opens up new possibilities for drug discovery.

1 April 2010 in Nature
Verified
Journal Article
Open access
PDF file
JFJulie A. Frearson
Julie A. Frearson
SBStephen Brand
Stephen Brand
SMStuart P. McElroy
Stuart P. McElroy
LCLaura A. T. Cleghorn
Laura A. T. Cleghorn
OSOndrej Smid
Ondrej Smid
PWPaul G. Wyatt
Paul G. Wyatt
African sleeping sickness or human African trypanosomiasis, caused by Trypanosoma brucei spp., is responsible for ∼30,000 deaths each year. Available treatments for this disease are poor, with unacceptable efficacy and safety profiles, particularly in the late stage of the disease when the parasite has infected the central nervous system. Here we report the validation of a molecular target and the discovery of associated lead compounds with the potential to address this lack of suitable treatments. Inhibition of this target—T. brucei N-myristoyltransferase—leads to rapid killing of trypanosomes both in vitro and in vivo and cures trypanosomiasis in mice. These high-affinity inhibitors bind into the peptide substrate pocket of the enzyme and inhibit protein N-myristoylation in trypanosomes. The compounds identified have promising pharmaceutical properties and represent an opportunity to develop oral drugs to treat this devastating disease. Our studies validate T. brucei N-myristoyltransferase as a promising therapeutic target for human African trypanosomiasis.

1 July 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MRManu De Rycker
Manu De Rycker
IHIrene Hallyburton
Irene Hallyburton
JTJohn Thomas
John Thomas
LCLorna Campbell
Lorna Campbell
SWSusan Wyllie
Susan Wyllie
DGDavid Gray
David Gray
Visceral leishmaniasis is a neglected tropical disease with significant health impact. The current treatments are poor, and there is an urgent need to develop new drugs. Primary screening assays used for drug discovery campaigns have typically used free-living forms of theLeishmaniaparasite to allow for high-throughput screening. Such screens do not necessarily reflect the physiological situation, as the disease-causing stage of the parasite resides inside human host cells. Assessing the drug sensitivity of intracellular parasites on scale has recently become feasible with the advent of high-content screening methods. We describe here a 384-well microscopy-based intramacrophageLeishmania donovaniassay and compare it to an axenic amastigote system. A panel of eight reference compounds was tested in both systems, as well as a human counterscreen cell line, and our findings show that for most clinically used compounds both axenic and intramacrophage assays report very similar results. A set of 15,659 diverse compounds was also screened using both systems. This resulted in the identification of seven new antileishmanial compounds and revealed a high false-positive rate for the axenic assay. We conclude that the intramacrophage assay is more suited as a primary hit-discovery platform than the current form of axenic assay, and we discuss how modifications to the axenic assay may render it more suitable for hit-discovery.

17 July 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ETEdwin G. Tse
Edwin G. Tse
SHSevan D. Houston
Sevan D. Houston
CWCraig Williams
Craig Williams
GSG. Paul Savage
G. Paul Savage
LRLouis M. Rendina
Louis M. Rendina
MTMatthew H. Todd
Matthew H. Todd
The replacement of one chemical motif with another that is broadly similar is a common method in medicinal chemistry to modulate the physical and biological properties of a molecule (i.e. bioisosterism). In recent years, bioisosteres such as cubane and bicyclo[1.1.1]pentane (BCP) have been used as highly effective phenyl mimics. Herein we show the successful incorporation of a range of phenyl bioisosteres during the open source optimization of an antimalarial series. Cubane (19) and closo-carborane (23) analogues exhibited improved in vitro potency against Plasmodium falciparum when compared to the parent phenyl compound, however these changes resulted in a reduction in metabolic stability; unusually, enzyme-mediated oxidation was found to take place on the cubane core. A BCP analogue (22) was found to be equipotent to its parent phenyl compound and showed significantly improved metabolic properties. While these results demonstrate the utility of these atypical bioisosteres when used in a medicinal chemistry program, the search to find a suitable bioisostere may well require the preparation of many candidates, in our case, thirty-two compounds.

10 June 2013 in RSC Advances
Verified
Journal Article
Open access
PDF file
MRMostafa E. Rateb
Mostafa E. Rateb
IHIrene Hallyburton
Irene Hallyburton
WHWael Houssen
Wael Houssen
ABAlan T. Bull
Alan T. Bull
MGMichael Goodfellow
Michael Goodfellow
RERainer Ebel
Rainer Ebel
An established culture of Aspergillus fumigatus MBC-F1-10 proved to be very receptive to external stimuli and reacted with the production of secondary metabolites which were undetectable when the fungus was grown under standard conditions. Firstly, co-cultivation with the type strain of Streptomyces bullii, an isolate from hyper-arid Atacama desert soil, led to the isolation of ergosterol 1, seven metabolites belonging to the diketopiperazine alkaloids; brevianamide F 2, spirotryprostatin A 3, 6-methoxy spirotryprostatin B 4, fumitremorgin C and its 12,13-dihydroxy derivative (5–6), fumitremorgin B 7, and verruculogen 8, in addition to 11-O-methylpseurotin A 9 and its new isomer 11-O-methylpseurotin A210. In an independent experiment, addition of N-butyryl-DL-homoserine lactone to the culture medium led to the production of emestrins A and B (11–12). Neither microbe produced these compounds when cultured alone. The structures of all compounds were elucidated using NMR spectroscopic techniques and mass spectrometric analysis. The isolated compounds were tested for their potential antibacterial and antiprotozoal activities.

31 July 2012 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
RPRoss A. Paveley
Ross A. Paveley
NMNuha R. Mansour
Nuha R. Mansour
IHIrene Hallyburton
Irene Hallyburton
LBLeo S. Bleicher
Leo S. Bleicher
ABAlex E. Benn
Alex E. Benn
QBQuentin D. Bickle
Quentin D. Bickle
Sole reliance on one drug, Praziquantel, for treatment and control of schistosomiasis raises concerns about development of widespread resistance, prompting renewed interest in the discovery of new anthelmintics. To discover new leads we designed an automated label-free, high content-based, high throughput screen (HTS) to assess drug-induced effects on in vitro cultured larvae (schistosomula) using bright-field imaging. Automatic image analysis and Bayesian prediction models define morphological damage, hit/non-hit prediction and larval phenotype characterization. Motility was also assessed from time-lapse images. In screening a 10,041 compound library the HTS correctly detected 99.8% of the hits scored visually. A proportion of these larval hits were also active in an adult worm ex-vivo screen and are the subject of ongoing studies. The method allows, for the first time, screening of large compound collections against schistosomes and the methods are adaptable to other whole organism and cell-based screening by morphology and motility phenotyping. Schistosomiasis is a severe helminth infection affecting an estimated 600 million people. The one drug widely available, praziquantel (PZQ), is not ideal. PZQ kills the adult worms but not the developing juveniles so the treated patient may not be cured long-term. In addition, use of repeated mass treatment campaigns with PZQ to control morbidity raises concerns about the development of drug resistance. Our work is aimed at providing starting points for drug discovery programs for schistosomiasis by screening large compound libraries against whole organisms. Praziquantel and several other known anti-schistosomal drugs are also active in vitro against the adult worms and the larval stages, schistosomula. The latter are ideal for novel drug screening as they can be produced in large numbers in vitro, are small and so are amenable to screening in microwell plates. Drug activity can be assessed visually but this is subjective and laborious. We have built an automated system for assessing drug action involving the collection of images of the larvae and the development of computer algorithms to analyze their morphology and motility, defining them as "hits" or "nonhits." The method is reliable, consistent and efficient, making it feasible, for the first time, to screen large compound collections.